Literature DB >> 856582

4-amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brain.

B Lippert, B W Metcalf, M J Jung, P Casara.   

Abstract

Incubation of rat brain 4-aminobutyrate aminotransferase with 4-amino-hex-5-enoic acid, a substrate analog of 4-aminobutyric acid, results in a time-dependent irreversible loss of enzymatic activity. In the presence of 0.1 mM inhibitor the half-life of the inactivation process is approximately 6 min. Low concentrations of L-glutamic acid or 4-aminobutyric acid protect against this inactivation, while 2-oxoglutarate prevents this protection, suggesting that only the pyridoxal form of the enzyme is susceptible to inhibition by 4-amino-hex-5-enoic acid. The irreversible inhibition of mammalian 4-aminobutyrate aminotransferase by 4-amino-hex-5-enoic acid is selective. There is no inhibition of this enzyme from Pseudomonas fluorescens with the inhibitor at mM concentrations. Even at 10 mM there is no irreversible inhibition of mammalian glutamate decarboxylase or of aspartate aminotransferase, while alanine aminotransferase is inhibited over 500 times more slowly than rat brain 4-aminobutyrate transaminase.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 856582     DOI: 10.1111/j.1432-1033.1977.tb11410.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  51 in total

1.  The 2011 E. B. Hershberg award for important discoveries in medicinally active substances: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile spasms.

Authors:  Richard B Silverman
Journal:  J Med Chem       Date:  2012-01-10       Impact factor: 7.446

2.  (1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a potent γ-aminobutyric acid aminotransferase inactivator for the treatment of cocaine addiction.

Authors:  Yue Pan; Madina R Gerasimov; Trine Kvist; Petrine Wellendorph; Karsten K Madsen; Elena Pera; Hyunbeom Lee; Arne Schousboe; Mary Chebib; Hans Bräuner-Osborne; Cheryl M Craft; Jonathan D Brodie; Wynne K Schiffer; Stephen L Dewey; Steven R Miller; Richard B Silverman
Journal:  J Med Chem       Date:  2011-12-30       Impact factor: 7.446

Review 3.  Clinical relevance of measuring GABA concentrations in cerebrospinal fluid.

Authors:  P J Schechter; A Sjoerdsma
Journal:  Neurochem Res       Date:  1990-04       Impact factor: 3.996

4.  Diverse effects of GABA-mimetic drugs on cocaine-evoked self-administration and discriminative stimulus effects in rats.

Authors:  Małgorzata Filip; Małgorzata Frankowska; Magdalena Zaniewska; Anna Gołda; Edmund Przegaliński; Jerzy Vetulani
Journal:  Psychopharmacology (Berl)       Date:  2007-01-26       Impact factor: 4.530

5.  Effects of gamma-vinyl GABA (vigabatrin) on blood pressure and body weight of hypertensive and normotensive rats.

Authors:  N Singewald; A Pfitscher; A Philippu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-02       Impact factor: 3.000

6.  Effect of elevated brain GABA concentrations on the actions of bicuculline and picrotoxin in mice.

Authors:  P J Schechter; Y Tranier
Journal:  Psychopharmacology (Berl)       Date:  1977-10-20       Impact factor: 4.530

7.  Regulatory interrelations between GABA and polyamines. I. Brain GABA levels and polyamine metabolism.

Authors:  N Seiler; G Bink; J Grove
Journal:  Neurochem Res       Date:  1979-08       Impact factor: 3.996

Review 8.  A risk-benefit assessment of vigabatrin in the treatment of neurological disorders.

Authors:  J Srinivasan; A Richens
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

Review 9.  Clinical pharmacology of vigabatrin.

Authors:  P J Schechter
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

10.  (4S)-4-amino-5,6-heptadienoic acid (MDL 72483): a potent anticonvulsant GABA-T inhibitor.

Authors:  S Sarhan; P Casara; B Knödgen; N Seiler
Journal:  Neurochem Res       Date:  1991-03       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.